Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema

Quality of Life Research

Volumn 18, Issue 7, 2009, Pages 929-939

  Vernon, Margaret K ^a   Rentz, Anne M ^a   Wyrwich, Kathleen W ^a   White, Martha V ^b   Grienenberger, Aurelie ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b Institute for Asthma and Allergy   (United States)

^c Dyax Corp   (United States)

Author keywords

Hereditary angioedema; Patient reported outcome; Psychometric validation

Indexed keywords

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; GLOBAL IMPROVEMENT MEASURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN SYMPTOM COMPLEX SEVERITY SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SWELLING; SYMPTOM; TEST RETEST RELIABILITY; TREATMENT OUTCOME; TREATMENT OUTCOME SCORE;

ADOLESCENT; ADULT; AGED; ANGIOEDEMA, HEREDITARY; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 69249217749     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-009-9509-8     Document Type: Article

References (31)

1. AE Davis 3rd 2004 Biological effects of C1 inhibitor Drug News & Perspectives 17 7 439 446
2. YT Huang YZ Lin HL Wu TF Chiu KM Lee HY Tsai et al. 2005 Hereditary angioedema: A family study Asian Pacific Journal of Allergy and Immunology 23 4 227 233
3. M Tosi 1998 Molecular genetics of C1 inhibitor Immunobiology 199 2 358 365
4. M Cicardi A Agostoni 1996 Hereditary angioedema New England Journal of Medicine 334 25 1666 1667
5. FA Bracho 2005 Hereditary angioedema Current Opinion in Hematology 12 6 493 498
6. K Bork G Meng P Staubach J Hardt 2006 Hereditary angioedema: New findings concerning symptoms, affected organs, and course American Journal of Medicine 119 3 267 274
7. K Bork J Hardt KH Schicketanz N Ressel 2003 Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency Archives of Internal Medicine 163 10 1229 1235
8. MM Gompels RJ Lock M Abinun CA Bethune G Davies C Grattan et al. 2005 C1 inhibitor deficiency: Consensus document Clinical and Experimental Immunology 139 3 379 394
9. JH Levy PS O'Donnell 2006 The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema Expert Opinion on Investigational Drugs 15 9 1077 1090
10. R Hays DA Revicki 2005
11. DA Revicki D Osoba D Fairclough I Barofsky R Berzon NK Leidy et al. 2000 Recommendations on health-related quality of life research to support labeling and promotional claims in the United States Quality of Life Research 9 8 887 900
12. NK Leidy DA Revicki B Geneste 1999 Recommendations for evaluating the validity of quality of life claims for labeling and promotion Value Health 2 2 113 127
13. Vernon, M. K., Rentz, A., White, M., & Schmalbach, T. (2007). Content validity and usability of the treatment outcome score and mean complex severity score: New electronic pros to assess symptom severity and improvement in hereditary angioedema. In 14th Annual Conference of the International Society for Quality of Life Research, Toronto, Ontario, Canada.
14. White, M., Vernon, M. K., Rentz, A., Beck, T. R., & Roberts, J. (2007). Development of a Patient-Reported Outcome (PRO) Measure to Assess Symptom Severity and Change in Hereditary Angioedema (HAE). The American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, Dallas, TX.
15. Vernon, M. K., Rentz, A. M., White, M. V., & Grienenberger, A. (2008). Validation of a Patient-Reported Outcome Measure to Assess Response to Treatment in Hereditary Angioedema. American College of Asthma, Allergy, & Immunology, Seattle, WA.
16. L Schneider W Lumry A Vegh AH Williams T Schmalbach 2007 Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor The Journal of Allergy and Clinical Immunology 120 2 416 422
17. M Kunschak W Engl F Maritsch FS Rosen G Eder G Zerlauth et al. 1998 A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema Transfusion 38 6 540 549
18. AT Waytes FS Rosen MM Frank 1996 Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate New England Journal of Medicine 334 25 1630 1634
19. S Saengpanich M deTineo RM Naclerio FM Baroody 2003 Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis Archives of Otolaryngology: Head & Neck Surgery 129 5 557 562
20. FE Simons BM Prenner A Finn Jr 2003 Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis The Journal of Allergy and Clinical Immunology 111 3 617 622
21. CB Small J Hernandez A Reyes E Schenkel A Damiano P Stryszak et al. 2005 Efficacy and safety of mometasone furoate nasal spray in nasal polyposis The Journal of Allergy and Clinical Immunology 116 6 1275 1281
22. DL Patrick LB Burke JH Powers JA Scott EP Rock S Dawisha et al. 2007 Patient-reported outcomes to support medical product labeling claims: FDA perspective Value Health 10 Suppl 2 S125 S137
23. RA Deyo P Diehr DL Patrick 1991 Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation Controlled Clinical Trials 12 4 Suppl 142S 158S
24. Streiner, D. L., & Norman, G. R. (2003). Health measurement scales. Oxford: Oxford University Press.
25. Scientific Advisory Committee of the Medical Outcomes Trust 2002 Assessing health status and quality-of-life instruments: Attributes and review criteria Quality of Life Research 11 3 193 205
26. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 1 159 174
27. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum.
28. JA Sloan T Symonds D Vargas-Chanes B Friedly 2003 Practical guidelines for assessing the clinical significance of heath related quality of life changes within clinical trials Drug Information Journal 37 23 31
29. KW Wyrwich NA Nienaber WM Tierney FD Wolinsky 1999 Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life Medical Care 37 5 469 478
30. KW Wyrwich WM Tierney FD Wolinsky 1999 Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life Journal of Clinical Epidemiology 52 9 861 873
31. GR Norman JA Sloan KW Wyrwich 2003 Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation Medical Care 41 5 582 592